drugset
drugset / Trial / NCT07606976

A Study of SSS68 Following a Single Subcutaneous Administration in Healthy Adult Participants

NCT07606976 ↗

Phase 1 Not yet recruiting 50 enrolled Shenyang Sunshine Pharmaceutical Co., LTD.
RandomizedSequentialTriple-blindOther

Summary

This is a randomized, double-blind, placebo-controlled, single ascending dose phase I clinical study to evaluate the safety, tolerability, PK, PD and immunogenicity of SSS68 in healthy adult participants following a single subcutaneous administration.

Timeline

Start
2026-06
Primary completion
2026-12
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject SSS68 Unknown 2 mg Subcutaneous
Subject SSS68 Unknown 50 mg Subcutaneous
Subject SSS68 Unknown 200 mg Subcutaneous
Subject SSS68 Unknown 400 mg Subcutaneous
Subject SSS68 Unknown 600 mg Subcutaneous
Subject SSS68 Unknown 900 mg Subcutaneous
Subject SSS68 Unknown 1200 mg Subcutaneous

Indications

No indication recorded.